Kbc Group Nv Biotechnology

Kbc Group Nv

$33.1 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
CLDX Celldex Therapeutics, Inc.	$1.26B	$71,000 0.0% of portfolio	2,081	Q3 2024 Added 31.21%
ARWR Arrowhead Pharmaceuticals, Inc.	$1.96B	$69,000 0.0% of portfolio	3,580	Q2 2024 Added 30.42%
KYMR Kymera Therapeutics, Inc.	$2.46B	$66,000 0.0% of portfolio	1,399	Q1 2024 New
RYTM Rhythm Pharmaceuticals, Inc.	$3.34B	$66,000 0.0% of portfolio	1,263	Q3 2023 Reduced 35.79%
LBPH Longboard Pharmaceuticals, Inc.	$812M	$65,000 0.0% of portfolio	1,954	Q3 2024 New
SNDX Syndax Pharmaceuticals Inc	$910M	$65,000 0.0% of portfolio	3,395	Q2 2024 New
CPRX Catalyst Pharmaceuticals, Inc.	$2.21B	$63,000 0.0% of portfolio	3,157	Q3 2023 Reduced 51.67%
VCEL Vericel Corp	$2.79B	$63,000 0.0% of portfolio	1,483	Q2 2024 Added 38.73%
XNCR Xencor Inc	$1.49B	$63,000 0.0% of portfolio	3,123	Q3 2024 Added 63.51%
MRUS Merus N.V.	$2.09B	$61,000 0.0% of portfolio	1,222	Q2 2024 Added 9.69%
ASND Ascendis Pharma A/S	$7.24B	$61,000 0.0% of portfolio	411	Q3 2024 New
PTGX Protagonist Therapeutics, Inc	$2.28B	$61,000 0.0% of portfolio	1,356	Q2 2024 Added 12.81%
LGND Ligand Pharmaceuticals Inc	$2.01B	$60,000 0.0% of portfolio	604	Q3 2023 Reduced 50.85%
SAVA Cassava Sciences Inc	$1.06B	$57,000 0.0% of portfolio	1,944	Q3 2024 New
IOVA Iovance Biotherapeutics, Inc.	$1.35B	$56,000 0.0% of portfolio	5,982	Q2 2024 Added 36.73%
IMVT Immunovant, Inc.	$3.55B	$55,000 0.0% of portfolio	1,936	Q3 2024 Added 46.22%
SWTX Spring Works Therapeutics, Inc.	$2.43B	$53,000 0.0% of portfolio	1,656	Q2 2024 Added 43.25%
NVAX Novavax Inc	$662M	$51,000 0.0% of portfolio	4,037	Q2 2024 New
BEAM Beam Therapeutics Inc.	$1.76B	$50,000 0.0% of portfolio	2,039	Q2 2024 Added 13.59%
RXRX Recursion Pharmaceuticals, Inc.	$1.03B	$50,000 0.0% of portfolio	7,602	Q3 2024 Added 79.93%
VERA Vera Therapeutics, Inc.	$1.31B	$48,000 0.0% of portfolio	1,090	Q1 2024 New
ACAD Acadia Pharmaceuticals Inc	$2.65B	$47,000 0.0% of portfolio	3,049	Q2 2024 New
ARDX Ardelyx, Inc.	$796M	$47,000 0.0% of portfolio	6,791	Q1 2024 New
INVA Innoviva, Inc.	$1.33B	$46,000 0.0% of portfolio	2,357	Q3 2023 Reduced 39.38%
BCRX Biocryst Pharmaceuticals Inc	$1.41B	$43,000 0.0% of portfolio	5,661	Q3 2024 Reduced 34.44%
HRMY Harmony Biosciences Holdings, Inc.	$2.02B	$41,000 0.0% of portfolio	1,025	Q3 2023 Reduced 48.27%
ARVN Arvinas, Inc.	$1.38B	$40,000 0.0% of portfolio	1,630	Q1 2024 New
RCKT Rocket Pharmaceuticals, Inc.	$1.07B	$39,000 0.0% of portfolio	2,109	Q1 2024 New
VIR Vir Biotechnology, Inc.	$944M	$28,000 0.0% of portfolio	3,793	Q2 2024 Added 50.58%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.